Home › Compound Library › d-Amphetamine

d-Amphetamine

Stimulantprescriptionoral · inferred

Dextro-enantiomer of amphetamine; the pharmacologically dominant isomer in mixed amphetamine salts and the sole species from lisdexamfetamine activation. t½ ~10 h (urine-pH dependent).

Projected serum levels — 10 mg, once daily

d-Amphetamine
d-Amphetamine modeled serum levels, 10 mg once daily over 15 days Population-based pharmacokinetic estimate. Steady state reached after approximately 1 days. 0 2.5 5 7.5 10 Day 0 Day 4 Day 8 Day 11 Day 15 Time on a regular schedule ≈ steady state · day 1
d-Amphetamine modeled serum levels with a loading dose of 12.8 mg, then 10 mg once daily The first dose is larger so levels approach steady state faster. 0 2.5 5 7.5 10 Day 0 Day 4 Day 8 Day 11 Day 15 Time on a regular schedule

Maintenance schedule: 10 mg once daily (oral).

Loading schedule: 12.8 mg on day 1, then 10 mg once daily — reaching therapeutic levels sooner.

Modeled steady state after ~1 days: peak ≈ 8.9 mg, trough ≈ 2.3 mg body load. Population-based estimate over 15 days for a 10 mg dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.

Key facts

Category
Stimulant
Route modeled
Oral
Model confidence
inferred
Half-life
11 h
Common dose
10 mg
Suggested maximum
60 mg/day
Reference dose range
5–60 mg (single dose)
Suggested cadence
once daily
Validated against
10 mg oral — Cmax 0.030 mg/L at 3 h

Documented interactions

  • danger
    1P-LSD (1-Propionyl-LSD) + d-Amphetamine Serotonin risk

    1P-LSD (1-Propionyl-LSD) and d-Amphetamine both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental status).

  • danger
    25I-NBOMe + d-Amphetamine Serotonin risk

    25I-NBOMe and d-Amphetamine both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental status).

  • danger
    2C-I (2,5-Dimethoxy-4-iodophenethylamine) + d-Amphetamine Serotonin risk

    2C-I (2,5-Dimethoxy-4-iodophenethylamine) and d-Amphetamine both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental status).

  • danger
    2C-B (4-Bromo-2,5-dimethoxyphenethylamine) + d-Amphetamine Serotonin risk

    2C-B (4-Bromo-2,5-dimethoxyphenethylamine) and d-Amphetamine both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental status).

  • danger
    4-AcO-DMT (Psilacetin) + d-Amphetamine Serotonin risk

    4-AcO-DMT (Psilacetin) and d-Amphetamine both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental status).

  • danger
    5-MeO-DMT (5-Methoxy-N,N-dimethyltryptamine) + d-Amphetamine Serotonin risk

    5-MeO-DMT (5-Methoxy-N,N-dimethyltryptamine) and d-Amphetamine both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental status).

Serum checks 108 modeled interaction pairings for d-amphetamine across your whole stack — absorption conflicts, enzyme inhibition, and nutrient depletion included.